SLU-PP-332 500

SLU-PP-332 is a specialized research reagent utilized primarily to investigate cellular energy metabolism, mitochondrial biogenesis, and the activation of estrogen-related receptors (ERRs). As a first-in-class, potent pan-agonist of ERR$\alpha$, ERR$\beta$, and ERR$\gamma$, it serves as a powerful "exercise mimetic" for exploring the transcriptional programs associated with physical endurance. Dragon Pharma provides SLU-PP-332 at a purity level of 99%+, specifically for use in in-vitro laboratory experiments and preclinical animal models.

Overview

In the realm of metabolic biochemistry and skeletal muscle physiology, SLU-PP-332 has emerged as a fundamental tool for investigators exploring the metabolic benefits of exercise without the requirement of physical exertion. Known scientifically as an ERR agonist, this small molecule offers the ability to study the upregulation of oxidative muscle fibers and enhanced fatty acid oxidation. Dragon Pharma provides SLU-PP-332 at a minimum purity of 99%, ensuring that researchers have access to a high-grade Research Compound capable of producing reproducible and accurate data in complex metabolic models.

As scientific inquiry into obesity-related metabolic dysfunction, sarcopenia, and cardiovascular resilience expands, the need for reliable ERR modulators like SLU-PP-332 has grown. This expanded profile examines the biochemical characteristics, structural integrity, and multifaceted research applications of SLU-PP-332.

Molecular Characteristics and Chemical Profile

The structural integrity of SLU-PP-332 allows it to bind specifically to the ligand-binding domain of the ERR family. By bypassing the need for natural co-activators like PGC-1$\alpha$, it directly initiates the expression of genes involved in mitochondrial function.

• Chemical Identity: SLU-PP-332
• Molecular Formula: $C_{26}H_{17}F_{3}N_{2}O_{3}S$
• Molecular Weight: 494.5 g/mol
• Purity: >99% (HPLC and Mass Spectrometry verified)
• Form: Crystalline powder / Lyophilized powder
• Manufacturer: Dragon Pharma

Source: PubChem

Research Applications

The compound is utilized in various scientific investigative domains, including:

• Mitochondrial Biogenesis: Mapping the increase in mitochondrial density and ATP production efficiency.
• Metabolic Programming: Investigating the shift from glycolytic (sugar-burning) to oxidative (fat-burning) metabolism.
• Lipid Oxidation: Studying the enhancement of fatty acid transport and beta-oxidation in muscle and liver models.
• Skeletal Muscle Fiber Transformation: Assessing the conversion of Type II (fast-twitch) to Type I (slow-twitch) oxidative fibers.
• Cardiovascular Resilience: Evaluating the role of ERRs in protecting the myocardium from metabolic stress and heart failure.

Pathway and Mechanistic Context

The core value of SLU-PP-332 in a laboratory setting is its ability to manipulate the ERR transcriptional axis independently of actual physical activity. In a natural physiological state, ERRs are orphan receptors that depend on co-activators to drive the "exercise program" in tissues.

The ERR-PGC-1$\alpha$ Metabolic Axis

Upon activation by SLU-PP-332, ERRs initiate a global shift in cellular behavior. This promotes the energy-producing catabolic pathways that mimic the cellular response to endurance training.

Key Mechanistic Shifts:

• Exercise Mimicry: SLU-PP-332 facilitates the upregulation of genes involved in fatty acid uptake (CD36) and mitochondrial transport (CPT1b).
• Glycogen Sparing: It enhances the cell's capacity to utilize fat as fuel, providing a framework for studying blood glucose stability during metabolic stress.
• Antioxidant Defense: Researchers use SLU-PP-332 to observe the induction of mitochondrial antioxidant enzymes, which protect tissues from oxidative damage.

Primary Research Applications

1. Obesity and Metabolic Syndrome Research

SLU-PP-332 is heavily utilized in studies involving diet-induced obesity (DIO) models. In the United States, obesity rates show significant demographic variation: prevalence is approximately 49.9% among Non-Hispanic Black adults and 45.6% among Hispanic adults, compared to 41.4% in Non-Hispanic White adults. These disparities often correlate with a higher incidence of Type 2 Diabetes and metabolic syndrome. SLU-PP-332 provides a unique framework for investigating the chemical restoration of metabolic flexibility across these diverse research models.

2. Sarcopenia and Muscle Atrophy

Known in research circles for its "muscle-sparing" potential, SLU-PP-332 is used to observe how tissues adapt to sedentary or aging states. In preclinical trials, research models have demonstrated a 45% increase in running distance and a significant reduction in fat mass accumulation despite high-calorie intake, aiding the study of physical resilience in aged subjects.

3. Myocardial Energetics and Heart Failure

In cardiac research, SLU-PP-332 is investigated for its ability to maintain the energy supply of the heart. Research models focus on how ERR activation can mitigate the "metabolic collapse" associated with pressure-overload heart failure.

Form and Analytical Testing

At Dragon Pharma, the commitment to scientific accuracy begins with a rigorous manufacturing process. SLU-PP-332 is produced under strict laboratory conditions to ensure the compound remains stable and potent.

• Stability and Purity: The compound is optimized for long-term stability, removing synthesis byproducts that could interfere with nuclear receptor binding assays.
• Rigorous Analytical Verification: To guarantee a purity level of 99% or higher, every batch undergoes High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to confirm that the chemical signature matches the verified SLU-PP-332 profile.